Oriental Carbon [OCCL] vs Chemo-Pharma [CPL] Detailed Stock Comparison
Oriental Carbon
NSE
Loading...
Chemo-Pharma
BSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Oriental Carbon wins in 10 metrics, Chemo-Pharma wins in 9 metrics, with 0 ties. Oriental Carbon appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Oriental Carbon | Chemo-Pharma | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 77.41 | 11.95 | Chemo-Pharma |
| Price-to-Book Ratio | 0.87 | 2.52 | Oriental Carbon |
| Debt-to-Equity Ratio | 0.01 | 44.70 | Oriental Carbon |
| PEG Ratio | -1.00 | 0.61 | Oriental Carbon |
| EV/EBITDA | 10.41 | 13.68 | Oriental Carbon |
| Profit Margin (TTM) | 9.67% | 11.11% | Chemo-Pharma |
| Operating Margin (TTM) | 18.99% | 9.62% | Oriental Carbon |
| EBITDA Margin (TTM) | 18.99% | 9.62% | Oriental Carbon |
| Return on Equity | 1.17% | 20.97% | Chemo-Pharma |
| Return on Assets (TTM) | 0.94% | 11.26% | Chemo-Pharma |
| Free Cash Flow (TTM) | $23.96M | $41.66M | Chemo-Pharma |
| Dividend Yield | 2.84% | N/A | N/A |
| 1-Year Return | -6.68% | -10.86% | Oriental Carbon |
| Price-to-Sales Ratio (TTM) | 2.15 | 1.39 | Chemo-Pharma |
| Enterprise Value | $2.33B | $4.59B | Chemo-Pharma |
| EV/Revenue Ratio | 2.15 | 1.57 | Chemo-Pharma |
| Gross Profit Margin (TTM) | 41.04% | 29.30% | Oriental Carbon |
| Revenue per Share (TTM) | $108 | $51 | Oriental Carbon |
| Earnings per Share (Diluted) | $3.01 | $5.66 | Chemo-Pharma |
| Beta (Stock Volatility) | 0.06 | 0.23 | Oriental Carbon |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Oriental Carbon vs Chemo-Pharma Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Oriental Carbon | 0.00% | 0.19% | -26.15% | 34.10% | 13.10% | 1.00% |
| Chemo-Pharma | -0.63% | 1.22% | -10.60% | -11.27% | -19.24% | -41.64% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Oriental Carbon | -6.68% | -72.39% | -70.42% | -54.26% | -54.26% | -54.26% |
| Chemo-Pharma | -10.86% | 284.53% | 120.36% | 729.71% | 1,225.59% | 1,225.59% |
News Based Sentiment: Oriental Carbon vs Chemo-Pharma
Oriental Carbon
News sentiment data is not available for Oriental Carbon at this time.
Chemo-Pharma
News based Sentiment: NEGATIVE
The significant financial losses reported in Q1 FY26, coupled with underperformance relative to the Sensex, create a concerning picture for investors. While the diversification strategy is a positive development, it doesn't immediately offset the current challenges. The volatile stock price and fluctuating investor participation add to the uncertainty.
Performance & Financial Health Analysis: Oriental Carbon vs Chemo-Pharma
| Metric | OCCL | CPL |
|---|---|---|
| Market Information | ||
| Market Cap | ₹2.33B | ₹4.05B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 11,979 | 32,878 |
| 90 Day Avg. Volume | 90,999 | 33,955 |
| Last Close | ₹233.34 | ₹67.44 |
| 52 Week Range | ₹132.00 - ₹400.00 | ₹66.00 - ₹128.00 |
| % from 52W High | -41.67% | -47.31% |
| All-Time High | ₹1,599.70 (Jan 01, 2018) | ₹128.00 (Jan 06, 2025) |
| % from All-Time High | -85.41% | -47.31% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.89% | 0.08% |
| Quarterly Earnings Growth | 11.88% | 0.34% |
| Financial Health | ||
| Profit Margin (TTM) | 0.10% | 0.11% |
| Operating Margin (TTM) | 0.19% | 0.10% |
| Return on Equity (TTM) | 0.01% | 0.21% |
| Debt to Equity (MRQ) | 0.01 | 44.70 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹266.61 | ₹26.86 |
| Cash per Share (MRQ) | N/A | ₹1.01 |
| Operating Cash Flow (TTM) | ₹80.93M | ₹277.99M |
| Levered Free Cash Flow (TTM) | ₹1.11B | ₹313.23M |
| Dividends | ||
| Last 12-Month Dividend Yield | 2.84% | N/A |
| Last 12-Month Dividend | ₹7.00 | ₹0.00 |
Valuation & Enterprise Metrics Analysis: Oriental Carbon vs Chemo-Pharma
| Metric | OCCL | CPL |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 77.41 | 11.95 |
| Forward P/E | 21.18 | N/A |
| PEG Ratio | -1.00 | 0.61 |
| Price to Sales (TTM) | 2.15 | 1.39 |
| Price to Book (MRQ) | 0.87 | 2.52 |
| Market Capitalization | ||
| Market Capitalization | ₹2.33B | ₹4.05B |
| Enterprise Value | ₹2.33B | ₹4.59B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 2.15 | 1.57 |
| Enterprise to EBITDA | 10.41 | 13.68 |
| Risk & Other Metrics | ||
| Beta | 0.06 | 0.23 |
| Book Value per Share (MRQ) | ₹266.61 | ₹26.86 |
Financial Statements Comparison: Oriental Carbon vs Chemo-Pharma
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | OCCL | CPL |
|---|---|---|
| Revenue/Sales | ₹278.32M | ₹697.42M |
| Cost of Goods Sold | ₹164.11M | ₹493.08M |
| Gross Profit | ₹114.22M | ₹204.34M |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹15.30M | ₹67.12M |
| EBITDA | ₹33.68M | ₹79.31M |
| Pre-Tax Income | ₹18.22M | ₹55.13M |
| Income Tax | ₹3.12M | ₹12.13M |
| Net Income (Profit) | ₹15.10M | ₹42.99M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | OCCL | CPL |
|---|---|---|
| Cash & Equivalents | ₹28.43M | ₹12.05M |
| Total Current Assets | ₹1.26B | ₹2.51B |
| Total Current Liabilities | ₹181.37M | ₹1.17B |
| Long-Term Debt | ₹12.28M | ₹109.50M |
| Total Shareholders Equity | ₹2.96B | ₹1.49B |
| Retained Earnings | N/A | N/A |
| Property, Plant & Equipment | ₹681.78M | ₹144.04M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | OCCL | CPL |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | OCCL | CPL |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 11,979 | 32,878 |
| Average Daily Volume (90 Day) | 90,999 | 33,955 |
| Shares Outstanding | 9.99M | 57.55M |
| Float Shares | 4.50M | 17.06M |
| % Held by Insiders | 0.53% | 0.70% |
| % Held by Institutions | 0.05% | 0.00% |
Dividend Analysis & Yield Comparison: Oriental Carbon vs Chemo-Pharma
| Metric | OCCL | CPL |
|---|---|---|
| Last 12-Month Dividend | ₹7.00 | ₹0.00 |
| Last 12-Month Dividend Yield | 2.84% | N/A |
| 3-Year Avg Annual Dividend | ₹11.67 | ₹0.00 |
| 3-Year Avg Dividend Yield | 1.10% | N/A |
| 3-Year Total Dividends | ₹35.00 | ₹0.00 |
| Ex-Dividend Date | Jul 23, 2024 | N/A |